GeoVax's AIDS (HIV-1) Vaccines, initially developed at Emory University by Dr. Harriet Robinson, currently GeoVax's Senior Vice President of Research and Development, in collaboration with researchers at the NIAID (NIH) and the U.S. Centers for Disease Control (CDC), are recombinant DNA and MVA vaccines. Our focus is on developing AIDS vaccines comprising the major HIV-1 subtypes (A, B and C). These vaccines can be used alone or in combination depending on a local infection. Our first priority is subtype B which is most common in North America, the European Union, Japan and Australia.
When administered in series, our AIDS vaccines induce strong cellular and humoral immunity (protection) in non human primates against multiple HIV-1 (AIDS virus) proteins. This suggests that GeoVax's vaccines will provide protection against the development of AIDS in HIV-1 virus infected people.